Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.

@article{Lu2007EpidermalGF,
  title={Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.},
  author={Yang Lu and Xinqun Li and K X Liang and Rodney Brian Luwor and Zahid H. Siddik and Gordon B. Mills and John Mendelsohn and Zhen Xing Fan},
  journal={Cancer research},
  year={2007},
  volume={67 17},
  pages={8240-7}
}
Cetuximab is an epidermal growth factor receptor (EGFR)-blocking antibody that has been approved for treatment of patients with metastatic colorectal cancer. In this study, we investigated biochemical changes in signaling pathways of a cetuximab-resistant subline of DiFi colorectal cancer cells (DiFi5) that was developed by exposing the parental sensitive cells to subeffective doses of cetuximab over an extended period of time. Compared with parental DiFi cells that express high levels of EGFR… CONTINUE READING